Slides Airfinity – 5th GLOBAL BIOPHARMA CEO / TOP EXECS VIRTUAL PRESS BRIEFING – COVID-19 (8 December 2020)

Report 29 Jul 2026

Healthy planet, healthy people: The innovative pharmaceutical industry’s contribution to the Kunming-Montreal Global Biodiversity Framework

Human health and nature are deeply interconnected. Land-use change, climate change, and pollution drive biodiversity loss and reshape the environmental conditions on which human well-being depends. Land-use change increases the risk of zoonotic spillover and emerging infectious diseases; climate change alters the distribution of vector- and waterborne diseases and stresses threatened species; and pollution adds...

Global biopharmaceutical CEOs response to reforms introduced in Germany

In response to reforms adopted by the German government on 10 July, BCR Secretary General, and IFPMA Director General, Dr. David Reddy, said: “The legislation passed by the German government undermines the value of medical innovation, global competitiveness and patient access to new medicines. Failing to reflect the value that medicines and vaccines bring, will negatively...

Statement on PABS Instrument at the seventh meeting of the Intergovernmental Working Group (IGWG 7) on the WHO Pandemic Agreement

On 6 July 2026, IFPMA delivered a statement ahead of the seventh meeting of the Intergovernmental Working Group (IGWG 7) on the WHO Pandemic Agreement.